Solid Biosciences prices $200M public offering of common stock and pre-funded warrants

Solid Biosciences Inc.

Priced public offering of 35.7M shares at $4.03/share and pre-funded warrants for 13.9M shares at $4.029 each; gross proceeds ~$200M.
Net proceeds estimated at $187.5M after underwriting discounts and expenses; offering expected to close Feb 19, 2025.
Investors include Adage Capital Partners, Bain Capital Life Sciences, Invus, Perceptive Advisors, RA Capital Management, others.
Jefferies, Leerink Partners, William Blair act as joint book-runners; H.C. Wainwright as lead manager.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.